Cancer clinical trials in the region Île-de-France
357 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06319820
Non-invasive bladder cancer
Localized
FGFR
None
1
2
3 or more
Gustave Roussy (Villejuif), Hôpital Pitié Salpêtrière - AP-HP (Paris), Hôpital Saint Louis AP-HP (Paris), Hôpital Bichat - Claude Bernard - AP-HP (Paris)
Janssen
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT05024773
Non-invasive bladder cancer
Urothelial carcinoma
Localized
1
Immunotherapy
Systemic Treatment-Naive
Systemic Treatment-Naive
Hôpital Bichat - Claude Bernard - AP-HP (Paris)
Fidia Farmaceutici s.p.a.
Phase 3
Breast cancer
#NCT05552001
HER2 Negative
HR Negative
Locally Advanced
Metastatic
1
Surgery
Immunotherapy
Chemotherapy
Radiotherapy
Surgery
Chemotherapy
Targeted therapy
Radiotherapy
Systemic Treatment-Naive
Gustave Roussy (Villejuif)
Institut Gustave Roussy
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT05911295
Invasive bladder cancer
Upper excretory tract cancer
Urethral cancer
Urothelial carcinoma
Locally Advanced
Metastatic
HER2
None
Systemic Treatment-Naive
Immunotherapy
Gustave Roussy (Villejuif)
Seagen